Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Octreotide inhibits HepG2 proliferation, study confirms

Octreotide inhibits HepG2 proliferation, study confirms

Study finds E2F5 transcription factor commonly overexpressed in primary human HCC

Study finds E2F5 transcription factor commonly overexpressed in primary human HCC

Researchers propose new classification system for SOD

Researchers propose new classification system for SOD

Research sheds new light on venous thromboembolism following liver resections

Research sheds new light on venous thromboembolism following liver resections

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

MRI T2 can determine iron overload in beta-thalassemic patients

MRI T2 can determine iron overload in beta-thalassemic patients

Researchers study peripheral blood Tregs as disease marker of gastric cancer

Researchers study peripheral blood Tregs as disease marker of gastric cancer

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Fibroblasts help 'recruit' immune cells for tumor growth

Fibroblasts help 'recruit' immune cells for tumor growth

Survival following transplant surgery for liver cancer not impacted by HIV-positive status

Survival following transplant surgery for liver cancer not impacted by HIV-positive status

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Scientists identify prognostic biomarker to treat patients with HCV

Scientists identify prognostic biomarker to treat patients with HCV

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Tekmira begins patient dosing in TKM-PLK1 phase 1 trail for cancer

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Researchers present definitive explanation of how fibrotic cells destroy human liver

Researchers present definitive explanation of how fibrotic cells destroy human liver

New study finds racial, ethnic disparities in cancer treatment

New study finds racial, ethnic disparities in cancer treatment

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.